NCT00977951 - Genomic Changes Associated With the Use of Intradermal Avotermin (Juvista) in Small Wounds in Healthy Male Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2002

Primary Completion Date

September 30, 2003

Study Completion Date

September 30, 2003

Conditions

CicatrixWound Healing

Interventions

DRUG

Intradermal avotermin

50 ng/100 ul avotermin administered intradermally prior to wounding (day 0) and again 24 h later on day 1. Wounds were dosed again prior to wound excision on day 3 and again on day 4

DRUG

Intradermal avotermin

50 ng/100 ul avotermin administered intradermally prior to wounding (day 0) and again 24 h later on day 1. Wounds were dosed again prior to wound excision on day 5 and again on day 6

DRUG

Placebo (vehicle)

Placebo administered intradermally prior to wounding (day 0) and again 24 h later on day 1. Wounds were dosed again prior to wound excision on day 3 and again on day 4

DRUG

Placebo

50 ng/100 ul avotermin administered intradermally prior to wounding (day 0) and again 24 h later on day 1. Wounds were dosed again prior to wound excision on day 5 and again on day 6

Trial Locations (1)

M13 9XX

Renovo Ltd, Manchester

All Listed Sponsors

lead

Renovo

INDUSTRY